STOCKS TELEGRAPH

Tag: INmune Bio

  • After-Market Momentum: INmune Bio (INMB) Shares Leap On Clinical Trial News

    After-Market Momentum: INmune Bio (INMB) Shares Leap On Clinical Trial News

    During extended trading hours, INmune Bio, Inc. (NASDAQ: INMB) had a notable spike, with its shares rising 83.28% to $11.51. This upswing followed a regular session decline of 14.79%, where INMB stock closed at $6.28. Following the company’s release of impending findings from its Phase 2 MINDFuL clinical study, which targets early Alzheimer’s Disease (AD), a significant milestone in its research pipeline, there was turbulence.

    Upcoming Conference Call and Trial Overview

    On Monday, June 30, INmune Bio (INMB) will have a conference call to provide the top-line results of the Phase 2 MINDFuL study, which assesses the effectiveness of its experimental medication, XPro, in treating individuals with early-stage Alzheimer’s disease. INmune Bio showcased baseline data and participant biomarker profiles at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD) in Vienna earlier this year, where it revealed first findings.

    With an average participant age of 72, the MINDFuL experiment is a blinded, randomized research that includes people with moderate AD or mild cognitive impairment (MCI). Over the course of 23 weeks, subjects were randomized in a 2:1 ratio to receive weekly subcutaneous injections of either 1.0 mg/kg of XPro or a placebo.

    Trial Endpoints and Patient Characteristics

    The primary endpoint of the trial is the change in cognitive performance using the Early and Mild Alzheimer’s Cognitive Composite (EMACC), a tool specifically designed for early-stage AD trials. EMACC scores at baseline were higher in MCI patients and strongly correlated with other validated scales like MMSE and CDR-SB. Notably, 69.2% of participants were APOE ε4 carriers, and 64.4% met inclusion criteria for more than one inflammatory biomarker.

    Secondary Measures and Future Updates

    Secondary outcomes include assessments using CDR-SB, E-Cog, ADL, the Neuropsychiatric Inventory (NPI), blood-based biomarkers, and neuroimaging. The patient cohort showed remarkable similarity to those in successful Phase III studies. INmune Bio (INMB) had previously indicated plans to release topline MINDFuL trial results by June, a catalyst that has now ignited renewed investor interest in its shares.

  • Pre Market Report: Stock Watch Ahead Of U.S Markets Opening

    Pre Market Report: Stock Watch Ahead Of U.S Markets Opening

    U.S markets are showing signs of a rebound after a weak showing in Monday’s session. Nonetheless, market sentiment remains mixed. On the downside, there are fears that the economy could be headed for another shutdown as the coronavirus numbers continue to rise. States like California are slowing down on reopening to curtail the virus spread. There are also concerns about equities being overpriced. Most companies have taken a hit in their revenues, yet the stock market has rallied back to pre-crisis levels. This indicates a disconnect between stock market valuations and corporate performance. On the positive side, the U.S government appears ready to keep supporting the economy. Today, The New York Times has reported that the Trump administration is calling for a payroll tax cut, relief for distressed industries, and a tax holiday on capital gains. The New York Times further states that the next stimulus could be between $1 trillion to $3 trillion. While this adds to the already ballooning deficit, it offers critical support to the economy, and more specifically the equity markets.  In spite of the mixed outlook, there are stocks that are on a roll pre-market and could perform well in the day. Some of them are as below.

    Tesla [NASDAQ: TLSA]

    Tesla continues its stellar performance and is up by over 6% pre-market. The stock has been on an exponential growth path driven by its sales numbers, and a growing appetite for stocks in the market. Tesla recently announced that in Q2, it had delivered 90,650 units, beating its estimates of 74,130 units.  Some analysts believe that this points to growing demand for the company’s vehicles, which is playing to support its stock price. A JP Morgan recently stated that Tesla was now set to break even on GAAP in Q2, a factor that is changing the market’s risk evaluation of the stock. With such optimism at play, TLSA could continue its rally if the market opens in positive territory.

    INmune Bio Inc [NASDAQ: INMB]

    INmune Bio is another big mover pre-market and is up by 142.82% at the time of writing. The rally comes hours after the company released interim data showing that its treatment called XPro1595 reduces neuroinflammation in people suffering from Alzheimer’s disease. XPro1595 is an inhibitor for tumor necrosis factor that neutralizes soluble TNF, and with implications on the pathology of Alzheimer’s. Commenting on the results, the company’s director of neuroscience, CJ Barnum stated that they were happy with the findings. The response the stock has received pre-market shows that investors are optimistic that this could be a major breakthrough not just for Alzheimer’s patients, but also for the company’s bottom-line.

    ElectroCore Inc [NADAQ: ECOR]

    ElectroCore was a top gainer in yesterday’s session and closed with gains of 109.41%. The stock seems poised to continue this rally and is up by 6% in pre-market trading. The upside momentum is driven by the company’s announcement that it had received emergency use authorization from the FDA for its COVID-19 treatment.  The company stated that it was now working on making its new therapy available to medics treating COVID-19 patients that have asthma and other breathing difficulties,